Intercept Pharmaceuticals Inc (ICPT) Stock
ICPT is no longer traded. Intercept Pharmaceuticals was delisted from the Nasdaq in November 2023.
Prices on this page are historical; the last trade was November 7, 2023 at $19.00.
Intercept Pharmaceuticals stock price history
ICPT final trading statistics
- Final close
- $19.00
- Final trading day
- Nov 7, 2023
- Market cap at delisting
- $794.69M
- Shares outstanding
- 41.83M
- Final 52-week range
- $8.82 – $21.86
- Avg. volume (final 3 mo.)
- 2,105,267
- All-time high (split-adj.)
- $462.26 · Mar 2014
- All-time low (split-adj.)
- $9.17 · May 2023
- Return since IPO
- +52.4%
- Beta
- 0.88
- Book value / share
- $1.72
- Price / book
- 11.06
Intercept Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $285.71M | $115.2M | $6.04 |
| FY2021 | $363.47M | -$145.0M | -$3.41 |
| FY2020 | $312.69M | -$324.2M | -$7.97 |
| FY2019 | $252.00M | -$391.1M | -$10.89 |
| FY2018 | $179.80M | -$309.2M | -$10.95 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Intercept Pharmaceuticals stock FAQ
What happened to Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $19.00 on November 7, 2023.
Is ICPT stock still trading?
No. ICPT was delisted from the Nasdaq in November 2023 and no longer trades on a U.S. exchange.
What was the last price of ICPT stock?
ICPT closed at $19.00 on its final trading day, November 7, 2023, for a market value of about $794.69M.
What were Intercept Pharmaceuticals's revenue and earnings in its last full fiscal year?
Intercept Pharmaceuticals reported revenue of $285.71M and net income of $115.2M in fiscal 2022, its last full year as a public company.
When did Intercept Pharmaceuticals go public?
Intercept Pharmaceuticals Inc stock began trading on October 11, 2012.